为成人和青少年新型结核病疫苗的公平全球获取和可持续融资提供催化解决方案

Catalysing solutions forequitable global access andsustainable financing for Catalysing solutions for equitable global access and sustainable financing ISBN 978-92-4-011690-0 (electronic version)ISBN 978-92-4-011691-7 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes,provided the work is appropriately cited, as indicated below. In any use of this work, there should be nosuggestion that WHO endorses any specific organization, products or services. The use of the WHO logo isnot permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Any mediation relating to disputes arising under the licence shall be conducted in accordance with themediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation.Catalysing solutions for equitable global access and sustainable financing for noveltuberculosis vaccines for adults and adolescents. Geneva: World Health Organization; 2025. Licence: Cataloguing-in-Publication (CIP) data.CIP data are available athttps://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders.To submit requests for commercial use and queries on rights and licensing, seehttps://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such astables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and General disclaimers.The designations employed and the presentation of the material in this publicationdo not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsedor recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and All reasonable precautions have been taken by WHO to verify the information contained in this publication.However, the published material is being distributed without warranty of any kind, either expressed or implied. Contents ForewordAcknowledgementsAbbreviationsExecutive summary 2.4.2 Objectives2.4.3 Methodology2.4.4 Results overview2.4.5 Comparison of demand and supply projections18 01Introduction 1.1 Background1.2 A vision for equitable access to novel TB vaccines 2.5 Financing landscape 2.5.1 Introduction2.5.2 Objectives2.5.3 Key findings from financing landscape 02Landscape and evidence to date3 2.1.1 Introduction2.1.2 Objectives2.1.3 Key findings from country consultations 03Solutions and roadmap24 3.1 Summary of key identified gaps243.2 Proposed solutions and mechanisms263.3 Call to action323.4 Next steps32 2.2 Demand projections 2.2.1 Introduction2.2.2 Objectives2.2.3 Methodology2.2.4 Results overview References Annexes 2.3 Product licensing and access strategies 2.3.1 Introduction2.3.2 Objectives2.3.3Key findings from supply Annex 4Supply projectionsand Annex 5 Financing LandscapeAnnex 6 Financing gap modellingAnnex 7 List of mechanisms 2.4Supply projections and comparisonagainst demand 2.4.1 Introduction Foreword Tuberculosis (TB) is one of the world’s deadliest infectiousdiseases. Despite global commitments to end TB by 2030,progress is fragile. Every year, more than 10 million people fall financing institutions, and civil society to coordinate globalefforts across the vaccine value chain, from research anddevelopment through manufacturing and regulatory readiness Global efforts to combat TB have saved an estimated 79 millionlives between 2000 and 2023. However, drastic cuts in healthfinancing, rising drug resistance and disruptions to health We know from prior experience that finance and accessconsiderations are critical to accelerate vaccine rollout. As thescience moves forward, pathways for ensuring equity andaccess must be included in early plans for manufacturing. In The World Health Organization (WHO) is committed tosupporting science to find new solutions to fight TB. More thana century after the introduction of BCG, the only licensed TB This report represents one of the first outputs of the TB VaccineAccelerator’s Finance and Access Working Group, reflectinginsights from the group itself, as well as from high-burden WHO estimates that, over 25 years, a vaccine for adolescentsand adults that is 50% effective could avert up to 76 million TBcases, 8.5 million deaths, 42 million courses of antibiotics andup to US$42 billion in costs faced by households affected by TB New TB vaccines have the potential to save millions of livesfaster and chang